Syneos Health

Syneos Health, Inc. engages in the provision of outsourced clinical development and commercialization services to biopharmaceutical companies. It operates through the following business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers clinical development services spanning Phase I to Phase IV, including global studies, as well as unbundled service offerings such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. The company was founded in 1998 and is headquartered in Morrisville, NC.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Syneos Health reports mixed Q4 results, focuses on growth strategies

Syneos Health's Q4 performance showed mixed results with revenue decline but growth on a constant currency basis. The company is focused on enhancing its operating model, customer engagement, and winning new business opportunities.
Challenges include evaluating spending by large pharma customers and the need for cost structure realignment. However, opportunities lie in engaging with analysts, driving cost savings, and expecting larger pharma awards in 2023.
Overall, Syneos Health remains confident in its strategy, investments, and ability to drive growth in Clinical. The company is navigating challenges while leveraging strengths in customer relationships and value-based pricing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.

Syneos Health Behavioral Scientist and Expert Communicator Team Up to Author Behavioral Insights Book – Proceeds Donated to The STARR Coalition Syneos Health Behavioral Scientist and Expert Communicator Team Up to Author Behavioral Insights Book – Proceeds Donated to The STARR Coalition

Syneos Health Introduces New Book, Why We Resist: The Surprising Truths About Motivating Behavior Change

New Offering Advances Traditional Outsourced Sales Model to Deliver Fully Optimized Field-Facing Commercialization Solutions New Offering Advances Traditional Outsourced Sales Model to Deliver Fully Optimized Field-Facing Commercialization Solutions

Syneos Health Showcases Evolved Deployment Solutions at Future Pharma in Boston

Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock?

Syneos Health (SYNH) Up 1.2% Since Last Earnings Report: Can It Continue?

Cerner

SYNH vs. CERN: Which Stock Is the Better Value Option?

SYNH or CERN: Which Is the Better Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing Syneos Health (SYNH) Right Now?

Syneos Health (SYNH) could produce exceptional returns because of its solid growth attributes.

3 Reasons Growth Investors Will Love Syneos Health (SYNH)

HMS Hlds

SYNH vs. HMSY: Which Stock Is the Better Value Option?

SYNH or HMSY: Which Is the Better Value Stock Right Now?

We are upbeat about Syneos Health's (SYNH) strong year-over-year revenue growth across both operating segments.

Syneos Health (SYNH) Q2 Earnings Beat Estimates, '19 View Up

Syneos Health, Inc. (SYNH) CEO Alistair MacDonald on Q2 2019 Results - Earnings Call Transcript

Why Is Syneos Health (SYNH) Up 4.6% Since Last Earnings Report?

Syneos Health (SYNH) sees strong year-over-year revenue growth across both operating segments ??? Clinical Solutions and Commercial Solutions.

Syneos' (SYNH) Q1 Earnings Miss Estimates, Revenues In Line

Syneos Health, Inc. (SYNH) CEO Alistair MacDonald on Q1 2019 Results - Earnings Call Transcript

Syneos Health (SYNH) delivered earnings and revenue surprises of -1.67% and 0.02%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Syneos Health (SYNH) Misses Q1 Earnings Estimates

Syneos Health (SYNH) Down 5.7% Since Last Earnings Report: Can It Rebound?

Medpace Holdings

PRA Health Sciences

These winning stocks don't make many headlines but are quietly delivering strong revenue and earnings growth.

3 Under-the-Radar Healthcare Stocks With Great Growth Potential

Medical technology stocks hit record highs last year and are spiking in 2019. Four of the fastest growing among them have tacked on double-digit earnings growth for several years.

Why These Fast-Growing Stocks Should Be On Your Radar: Syneos Health

Syneos Health stock popped Tuesday after the contract research organization delivered its delayed fourth-quarter sales and earnings beat.

Highly-Rated Medical Stock Pops After Delayed Report Tops Estimates

Syneos Health, Inc. (SYNH) CEO Alistair MacDonald on Q4 2018 Results - Earnings Call Transcript

News for Syneos Health Stock (SYNH)